1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,140 | 28.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tevogen Bio Inc: Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast | 1 | GlobeNewswire (USA) | ||
| Di | Tevogen Bio appoints new head of government affairs | 3 | Investing.com | ||
| Di | Tevogen Bio ernennt neuen Leiter für Regierungsangelegenheiten | 3 | Investing.com Deutsch | ||
| Di | Tevogen Bio Inc: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan | 48 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 15.03. | Wissenschaftlicher Leiter von Tevogen Bio verkauft Aktien im Wert von 253.935 US-Dollar | 2 | Investing.com Deutsch | ||
| 15.03. | Tevogen Bio's wissenschaftlicher Leiter verkauft Aktien im Wert von 253.935 US-Dollar | 1 | Investing.com Deutsch | ||
| 10.03. | Tevogen Bio reicht Patent für T-Zell-fokussierten Impfstoff ein | 2 | Investing.com Deutsch | ||
| 10.03. | Tevogen Bio Inc: Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO | 171 | GlobeNewswire (Europe) | Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company's lead product candidate TVGN 489, to mitigate the risk posed by... ► Artikel lesen | |
| 08.03. | Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft | 3 | Insider Monkey | ||
| 07.03. | Tevogen Bio Inc: Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel | 2 | GlobeNewswire (USA) | ||
| 04.03. | Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential | - | Benzinga.com | ||
| 04.03. | This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 5 | Benzinga.com | ||
| 04.03. | Boral Capital sets Tevogen stock Buy rating, $10 target | 3 | Investing.com | ||
| 03.03. | Tevogen Bio To Receive $8 Million In Grant Funding | 2 | pulse2.com | ||
| 03.03. | Tevogen Bio Inc: Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations | 121 | GlobeNewswire (Europe) | Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations... ► Artikel lesen | |
| 28.02. | Tevogen Bio Inc: Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy | 4 | GlobeNewswire (USA) | ||
| 21.02. | Tevogen Bio Inc: Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned | 123 | GlobeNewswire (Europe) | 600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU.Current ownership breakdown: Insiders 79%; Independent Board... ► Artikel lesen | |
| 17.02. | Tevogen Bio CEO reinforces commitment to retention of equity capital | 2 | Seeking Alpha | ||
| 15.02. | Tevogen Bio Inc: Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision | 137 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy... ► Artikel lesen | |
| 14.02. | Tevogen Bio Inc: Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency | 82 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
93 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,800 | -0,11 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| AMGEN | 283,45 | +0,50 % | Which Dow Jones Stock Is Cheaper, Amgen or Merck? | ||
| NOVAVAX | 6,433 | -0,66 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
| ILLUMINA | 73,70 | -0,26 % | Illumina Announces Board Changes: Scott Gottlieb Appointed Chair, Keith Meister Joins | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), an American biotechnology company, Tuesday has announced changes to its Board of Directors. Scott Gottlieb, MD, who has been a board member since... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,617 | +1,31 % | Palatin Techs Aktie: Positive Signale setzen! | Biotechnologieunternehmen erreicht wichtigen regulatorischen Durchbruch mit oralem Wirkstoff gegen genetisch bedingte Fettleibigkeit und verzeichnet Kursanstieg Palatin Technologies, Inc. (NYSE American:... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 592,00 | +0,68 % | Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows | ||
| ORGANOVO | 2,650 | 0,00 % | Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,550 | -3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,900 | -3,97 % | COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents | Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,184 | -0,39 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 66,46 | +0,76 % | BioMarin Pharmaceutical Inc.: BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO (vosoritide) in Children Under 3 with Achondroplasia at 2025 American ... | New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality... ► Artikel lesen | |
| EXELIXIS | 34,000 | +0,30 % | FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors | ||
| NUREXONE BIOLOGIC | 0,432 | -3,14 % | PTA-News: Small- & MicroCap Investment: NurExone: Erfolgreiche Präklinische Studie mit ExoPTEN | DJ PTA-News: Small- & MicroCap Investment: NurExone: Erfolgreiche Präklinische Studie mit ExoPTEN
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/23.03.2025/08:30) - NurExone Biologic... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 12,760 | 0,00 % | Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+3,85 %) liegt der Kurs bei 1,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.
